Boye, Kjetil http://orcid.org/0000-0002-5552-6283
Longhi, Alessandra
Guren, Tormod
Lorenz, Susanne
Næss, Stine
Pierini, Michela
Taksdal, Ingeborg
Lobmaier, Ingvild
Cesari, Marilena
Paioli, Anna
Løndalen, Ayca M.
Setola, Elisabetta
Hompland, Ivar
Meza-Zepeda, Leonardo A.
Sundby Hall, Kirsten
Palmerini, Emanuela
Funding for this research was provided by:
The Radium Hospital Foundation
Oslo University Hospital Trust
Merck Sharp and Dohme
University of Oslo
Article History
Received: 19 October 2020
Accepted: 27 January 2021
First Online: 12 February 2021
Compliance with ethical standards
:
: K. Boye has served on advisory board for Bayer and has received research support from Eli Lilly and Merck. E. Palmerini has served on an advisory board for Takeda, Amgen, Daiichi Sankyo, Eli Lilly, Eusa Pharma, and Deciphera, and has received other research support from Bristol Myers Squibb, Pfizer, PharmaMar, and Daiichi Sankyo.
: The study was approved by the institutional review boards and ethics committees of the involved institutions. It was conducted in accordance with the Declaration of Helsinki and according to Good Clinical Practice. The trial was registered with ClinicalTrials.gov, number NCT03013127, and all patients provided written informed consent before enrolment.